The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Akari Therapeutics Plc | COM | 00972G108 | 5,358 | 369,490 | SH | SOLE | 369,490 | 0 | 0 | ||
| Alcobra Ltd | COM | M2239P109 | 7,100 | 1,130,500 | SH | SOLE | 1,130,500 | 0 | 0 | ||
| ARCA biopharma Inc | COM | 00211Y100 | 5,017 | 1,078,932 | SH | SOLE | 1,078,932 | 0 | 0 | ||
| Ascendis Pharma A/S | COM | 04351P101 | 13,212 | 721,152 | SH | SOLE | 721,152 | 0 | 0 | ||
| Avalanche Biotechnologies Inc | COM | 05337G107 | 2,666 | 280,000 | SH | SOLE | 280,000 | 0 | 0 | ||
| Coherus Biosciences Inc | COM | 19249H103 | 5,953 | 259,259 | SH | SOLE | 259,259 | 0 | 0 | ||
| Cynapsus Therapeutics Inc | COM | 23257Y701 | 3,972 | 257,198 | SH | SOLE | 257,198 | 0 | 0 | ||
| CytomX Therapeutics Inc | COM | 23284F105 | 11,642 | 603,031 | SH | SOLE | 603,031 | 0 | 0 | ||
| DBV Technologies | COM | F2927N109 | 14,146 | 230,167 | SH | SOLE | 230,167 | 0 | 0 | ||
| Edge Therapeutics Inc | COM | 279870109 | 22,169 | 1,933,582 | SH | SOLE | 1,933,582 | 0 | 0 | ||
| Global Blood Therapeutics | COM | 37890U108 | 4,578 | 141,611 | SH | SOLE | 141,611 | 0 | 0 | ||
| Lipocine Inc | COM | 53630X104 | 5,431 | 420,000 | SH | SOLE | 420,000 | 0 | 0 | ||
| ProNAI Therapeutics Inc | COM | 74346L101 | 2,632 | 175,000 | SH | SOLE | 175,000 | 0 | 0 | ||
| REGENXBIO Inc | COM | 75901B107 | 15,874 | 1,030,954 | SH | SOLE | 1,030,954 | 0 | 0 | ||
| Stemline Therapeutics Inc | COM | 85858C107 | 1,994 | 315,980 | SH | SOLE | 315,980 | 0 | 0 | ||